New information from the UK suggests that protection from booster doses against Covit-19, a symptom caused by Ômicron variation, may decline in about ten weeks.
Survival Guide 2022:Experts plan scenes with Ômicron for next year’s corona virus infection
More severe micron cases are not yet sufficient for researchers to estimate the booster’s ability to protect against the more severe manifestations of the disease, but experts believe the extra dose may still be a significant ally against hospitalization and death.
“It will take a few weeks to evaluate the effectiveness of micronutrients against severe forms,” said a new report by the UK Health Safety Agency. Against symptomatic diseases. “
Since the discovery of Ômicron, several studies have suggested that this variant may avoid antibodies produced after vaccination or after coronavirus infection.
The new UK report, which includes data on people who have received the AstraZeneca, Pfizer or Moderna vaccines, confirmed that the vaccine – both the initial two-shot cycle and the booster dose – was less effective against Ômicron than Delta and was reduced faster.
Melatonin came to Brazil:What it is, what it is for and the benefits of the sleep hormone
In those who received two doses of the astrogenic vaccine, the booster, which contained one of the MRNA vaccines made by Pfizer and Moderna, was 60% effective in preventing symptomatic disease two to four weeks after injection. Ten weeks later, however, Pfizer’s booster was only 35% effective. The Modern Booster was 45% operational within nine weeks.
For those receiving a three-dose Pfizer, the effectiveness of the vaccine decreased from 70% after one week to 45% after 10 weeks. On the other hand, those who were vaccinated with Pfizer, who received the Moderna booster, seemed to perform better; Within nine weeks his vaccination system was up to 75% effective.
The report, which is based on an analysis of approximately 148,000 delta cases and 68,000 omigran cases, also includes recent data showing that infections caused by new strain are less likely to be hospitalized than delta cases. The findings should be interpreted with caution, the agency noted, because many cases of Ômicron are not yet available and those who contracted the variation may not be representative of the general public.
In a recent interview, Anthony S. Fauci, a U.S. epidemiologist, said it was too early to talk about a fourth dose in the country.
Some scientists oppose the fourth use. According to them, there is no evidence yet that this is necessary, and that certain cells in the immune system may eventually stop responding if overdose is administered.
“Music geek. Coffee lover. Devoted food scholar. Web buff. Passionate internet guru.”